MEDPLUS Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated May 15, 2026 3 min read

Medplus Health Services continues its aggressive retail expansion strategy, balancing the push for store-level growth with an ongoing shift toward higher-margin private label products. Investors will be looking for updates on the FY26 store addition target, the sustainability of recent gross margin improvements, and the operational impact of recent regulatory drug license suspensions.

Quick Details

Results date	May 20, 2026
Quarter	Q4 FY 2025-2026
Previous quarter revenue	Rs. 18,061 million
Previous quarter PAT	Not stated
Previous quarter EBITDA margin	5.4%
Market cap	Rs. 10,824.72 Cr
CMP	Rs. 901.65

MEDPLUS Q4 Results Date and Time

The board meeting is scheduled for May 29, 2026, to consider and approve audited Standalone and Consolidated Financial Results for Q4 and FY ended March 31, 2026.

The Q4 FY26 earnings call is scheduled for May 21, 2026, at 16:00 IST.

What to expect from MEDPLUS's Q4 FY26 results

In its most recently reported quarter, Medplus posted revenue of Rs. 18,061 million and an EBITDA margin of 5.4%. The company added 182 net stores in Q3 FY26, bringing the total network to 5,112 units, with management pursuing a full-year target of 600 new stores. Private label products accounted for 22.2% of total revenue in Q3 FY26, and management continues to prioritize these items to support a steady-state gross margin target of 24.5% to 24.8%. The upcoming call will likely address the impact of recent drug license suspensions across 12 stores and the progress of the franchisee model pilot.

Key Things To Watch

Performance vs Guidance Tracking

Store Additions: 600 target for FY26 with 400 achieved YTD
Gross Margin: 24.5-24.8% steady-state target vs 26.2% reported in Q3
Pharmacy Operating EBITDA Margin: >5% target with 5.2% achieved in Q3

Strategic Expansion and Supply Chain

Status of franchisee model pilot and its role in meeting future growth targets
Completion of warehouse ramp-up in Tamil Nadu and Karnataka to improve fill rates
FY27 store addition outlook following internal AOP completion

Operational and Regulatory Focus

Same-store sales growth sustainability following the 10.5% recovery in Q3
Financial impact and compliance remediation following drug license suspensions under Rule 65
Cost trajectory of the employee retention plan for store-level staff

Frequently Asked Questions

When will Medplus announce Q4 FY 2025-2026 results?

The board is scheduled to meet on May 29, 2026, to consider and approve the financial results for the quarter and year ended March 31, 2026.

What was Medplus's revenue in its previous quarter?

Medplus reported consolidated revenue of Rs. 18,061 million for the third quarter of FY 2025-2026.

What is the status of Medplus's store expansion plan?

The company has added 400 net stores year-to-date through Q3 FY26 and is working toward a full-year target of 600 new stores.

How is Medplus addressing its recent drug license suspensions?

Management stated they are working with drug departments to correct issues and ensure compliance across the affected stores. The combined revenue impact from these suspensions was approximately Rs. 31.13 lakhs.

What is the company's strategy regarding private label products?

Medplus aims to grow private label penetration to improve gross margins, with private label sales reaching 22.2% of total revenue in Q3 FY26. Management targets a growth of approximately 0.5% quarterly on a net sales basis.